Extended thromboprophylaxis following lower limb arthroplasty: What do the clinical trials mean?

Haemostasis

Volumn 30, Issue SUPPL. 2, 2000, Pages 88-94

  Cohen, Alexander T ^a   Khushal, A ^b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Clinical thromboembolism; Orthopaedic surgery; Prevention; Prolonged prophylaxis; Symptomatic thromboembolism; Venography; Venous thromboembolism

Indexed keywords

ANTICOAGULANT AGENT; ARDEPARIN; DALTEPARIN; ENOXAPARIN; HEPARIN; LOW MOLECULAR WEIGHT HEPARIN; WARFARIN;

ARTHROPLASTY; BLEEDING; CLINICAL TRIAL; CONFERENCE PAPER; COST EFFECTIVENESS ANALYSIS; COST OF ILLNESS; DEEP VEIN THROMBOSIS; DRUG COST; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EMBOLISM; HIGH RISK PATIENT; HOSPITAL DISCHARGE; HUMAN; INCIDENCE; LONG TERM CARE; PHLEBOGRAPHY; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; TREATMENT INDICATION; VEIN THROMBOSIS;

EID: 0034456546     PISSN: 03010147     EISSN: None     Source Type: Journal    
DOI: 10.1159/000054171     Document Type: Conference Paper

References (28)

1. Risk of and prophylaxis for venous thromboembolism in hospital patients
2. Prevention of venous thromboembolism
3. Prevention of venous thrombembolism
4. A clinico-pathological study of fatal pulmonary embolism in a specialist orthopaedic hospital
5. Low molecular weight heparins for venous thromboembolism
6. Prophylaxis of postoperative thromboembolism with low molecular weight heparins
7. Low-molecular-weight heparin versus standard heparin in general and orthopaedic surgery: A meta-analysis
8. Low molecular weight heparin in prevention of perioperative thrombosis
9. Efficacy and safety of low molecular weight heparin, unfractionated heparin and warfarin for thromboembolism prophylaxis in orthopaedic surgery: A meta-analysis of randomised clinical trials
10. The incidence of symptomatic venous thromboembolism after enoxaparin prophylaxis in lower extremity arthroplasty. A cohort study of 1,984 patients
11. Anti-thrombotic strategy after total hip replacement. A cost-effectiveness analysis comparing prolonged anticoagulants with screening for deep vein thrombosis
12. Pulmonary embolism and its prophylaxis following the Charnley total hip replacement
13. Postoperative pulmonary embolism after hospital discharge. An underestimated risk
14. Incidence of venous thromboembolism verified by necroscopy over 30 years
15. Studies on coagulation, fibrinolysis, kallikrein-kinin and complement activation in systemic and pulmonary circulation during hip arthroplasty with acrylic cement
16. Sequential intrapulmonary and systemic activation of coagulation and fibrinolysis during and after total hip replacement surgery
17. Increased activation of coagulation and formation of late deep venous thrombosis following discontinuation of thromboprophylaxis after hip replacement surgery
18. Total hip replacement, lower limb blood flow and venous thrombogenesis
19. Post-discharge prevention of deep vein thrombosis following total joint replacement
20. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomised comparison of enoxaparin versus placebo
21. Low-molecular-weight heparin (enoxaparin) as prophylaxis against thromboembolism after total hip replacement
22. Prolonged thromboprophylaxis following hip replacement surgery - Results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Fragmin®)
23. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty - The Danish Prolonged Prophylaxis (DaPP) Study
24. Ardeparin Sodium for extended out-of-hospital prophylaxis against venous thromboembolism after total hip or knee replacement. A randomised, double-blind, placebo-controlled trial
25. A double blind randomised comparison of extended out-of-hospital prophylaxis using dalteparin versus placebo in patients undergoing elective hip replacement
26. An assessment of deep venous function following total hip arthroplasty complicated by venographically proven deep-vein thrombosis
27. Prevention of venous thromboembolism. International Consensus Statement. (Guidelines according to scientific evidence)
28. Routine use of adjusted low-dose warfarin to prevent venous thromboembolism after total hip replacement